MNK
Mallinckrodt Public Limited Company
Healthcare
10/13/2014
Presented
| Date | 10/06/2014 |
| Price | $91.32 |
| Market Cap | $10.40B |
| Ent Value | $12.27B |
| P/E Ratio | N/A |
| Book Value | $43.64 |
| Div Yield | N/A |
| Shares O/S | 113.67M |
| Ave Daily Vol | 2,780,000 |
| Short Int | 12.57% |
Current
| Price | no data |
| Market Cap | no data |
| Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide. The company’s Specialty Pharmaceuticals segment offers EXALGO extended-release tablets to treat chronic pain in opioid-tolerant patients; and GABLOFEN injections indicated for use in the management of spasticity of cerebral or spinal origin in patients age four years and above. This segment also provides generic pharmaceutical products, including acetaminophen products, oxycodone-containing tablets, hydrocodone-containing tablets, and methylphenidate HCl extended-release tablets USP (CII) to treat attention deficit hyperactivity disorder and addiction, as well as API products comprising hydrocodone and oxycodone; and medicinal opioids and synthetic controlled substances. This segment markets its branded products to physicians, including pain specialists, anesthesiologists, orthopedic surgeons, managed care organizations, and neurologists directly; and generic products to wholesalers, retail pharmacy chains, food store chains with pharmacies, mail order pharmacies, and hospital buying groups. Its Global Medical Imaging segment provides contrast media and delivery systems comprising ioversol and gadoversetamide injections for diagnostic imaging applications, such as computed tomography and magnetic resonance imaging under the Optiray and Optimark brands; and pre-filled syringes and proprietary power injectors. This segment also offers nuclear imaging agents consisting of technetium-99m generators under the Ultra-Technekow DTE brand; cold kits; and radiopharmaceuticals, such as Octreoscan kits for localization of tumors. This segment sells its contrast media systems to hospitals and imaging centers; and API products to other pharmaceutical companies directly or through distributors. The company is based in Dublin, Ireland.a |
Please note, this idea was updated on 2/12/2015 and can be read here: Long - Mallinckrodt PLC (MNK) (Update).
Publicly traded companies mentioned herein: Mallinckrodt (MNK)
Highlights
Mallinckrodt's previous acquisition of Questcor was fairly controversial, with multiple investors at the time maligning the deal's cash flow profile, but the company's base business is now increasing price at a significant rate. MNK's acquisition of Cadence Pharmaceuticals prior to the Questcor deal was highly accretive, and now Questcor - which was a highly underlevered acquisition - itself is starting to come on. The company now generates EBITDA of about $1.5 billion, and is led by a dynamic CEO who likely has an appetite for further acquisitions, according to the presenter.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.